Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the combination of izalontamab brengitecan Iza-bren with osimertinib compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy for participants with previously untreated, locally advanced or metastatic EGFR-mutant non-small cell lung cancer NSCLC. This Phase III randomized study aims to assess these treatments as first-line therapy in this patient population. Participants will receive one of the study treatments Iza-bren combined with osimertinib, osimertinib alone, or osimertinib combined with platinum-based chemotherapy including drugs such as pemetrexed, carboplatin, or cisplatin. Drug doses are specified on certain days, and treatment continues as per protocol. The study design is parallel and open-label with random assignment to one of the treatment arms. During the study, participants will be monitored through assessments including progression-free survival measured by blinded independent central review and investigator evaluation up to approximately three years. Additional evaluations include overall survival, objective response rates, disease control rates, and duration of response measured up to about five years. Safety and treatment effects will be closely observed throughout the study period which may last several years.